UBS hosted UnitedHealth management and said they gave compelling reasons to keep the Optum business together with its core business so as to maximize all potential opportunities. The company said if the benefits of running the two together erode over time they would consider spinning off Optum in whole or in pieces and even selling a portion to increase its financial flexibility. UBS reiterated its Buy rating and $140 price target on UnitedHealth shares.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here